About ImmuCell
ImmuCell is a company based in Portland (United States) founded in 1982. It operates as a Direct-to-Consumer (D2C) and Reseller / Distribution. The company has 75 employees. ImmuCell offers products and services including First Defense and Re-Tain.
- Headquarter Portland, United States
- Employees 75
- Stage Public
- SectorsAgriculture
- Phone•••• ••••
- Website immucell.com
- Social YouTube
- Legal Name Immucell Corporation
- Annual Revenue$27.64 M (USD)4.34as on Dec 31, 2025
- Net Profit-$1.04 M (USD)51.78as on Dec 31, 2025
- EBITDA$4.38 M (USD)318.23as on Dec 31, 2025
- Latest Funding Round$4.25 M (USD), Post-IPO
Apr 14, 2021
- Investors
- Employee Count75
Products & Services of ImmuCell
ImmuCell offers a comprehensive portfolio of products and services, including First Defense and Re-Tain.
Scours prevention for calves using colostrum-derived antibodies.
Intramammary treatment for subclinical mastitis in dairy.
Apps and channels of ImmuCell
its YouTube channel First Defense Calf Health has 67 subscribers and 30 videos.
Videos from ImmuCell
The most watched videos on ImmuCell's YouTube channel, First Defense Calf Health (67 subscribers). Click a video to play it here.
More on First Defense Calf Health.
Funding Insights of ImmuCell
- Total Rounds 4
- Last Round Post-IPO — $4.2M
- First Round $3.5M
(21 Oct 2016)
- Investors Count 1
All 4 funding rounds of ImmuCell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| 14 Apr 2021 | $4.2M | Post-IPO | – | – | – |
| 27 Jul 2017 | $1.1M | Post-IPO | – | – | – |
| 02 Mar 2017 | $2.0M | Debt – Conventional | – | – | |
| 21 Oct 2016 | $3.5M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in ImmuCell
ImmuCell has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include TD Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Financial services are offered through diverse subsidiaries. | 1955 | td.com | Portland, United States |
Investor details for ImmuCell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ImmuCell
12 people are tracked at ImmuCell (3 in leadership, 4 in board & advisors, 5 in team); the tracked headcount is 75.
| Name | Role | Group |
|---|---|---|
Bobbi Jo Brockmann | Vice President of Sales and Marketing, Director | Leadership |
Michael F. Brigham | President & CEO | Leadership |
Gustavo Scaffa | Senior Director Quality | Leadership |
David S. Tomsche | Chair of the Board | Board & advisors |
Paul R. Wainman | Director | Board & advisors |
Steven T. Rosgen | Director | Board & advisors |
Gloria Basse | Director Board of Directors | Board & advisors |
Michael Borges | Sales Manager | Team |
Nick Lawson | Quality Control Manager | Team |
Sarah Eck | Sales & Marketing Regional Manager | Team |
Rebecca Vincent | Sales Marketing Manager | Team |
Dale Miller | Territory Manager | Team |
Complete people profiles for ImmuCell
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ImmuCell
ImmuCell is a publicly listed company on the NASDAQ with ticker symbol ICCC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Apr 1987
- Listed onNASDAQ: ICCC
- Listed entityImmuCell Corporation
- Exchange sectorHealth technology
- ISINUS4525253062
- Share price$9.75 (+0.62% on the day) · 2026-10-08
- Market capitalisation$88.6M
- Price to earnings116.2
- EPS (diluted, trailing year)$0.08
- Volume (last session)5,099
Financials of ImmuCell
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $27.6M | -$1.0M | $4.4M |
| 2024 | $26.5M | -$2.2M | $1.1M |
| 2023 | $17.5M | -$5.8M | -$3.0M |
| 2022 | $18.6M | -$2.5M | $188,640 |
| 2021 | $19.2M | -$78,290 | $2.7M |
Detailed financial statements for ImmuCell
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of ImmuCell
4 dated milestones of ImmuCell across 39 years, from founding to its latest funding, stage changes and deals.
- Founded ImmuCell is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $3.5M.
- Funding Latest funding round, Post-IPO, of $4.2M.
Latest news on Immucell
Complete news archive for ImmuCell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ImmuCell
10 companies that operate in the same segment as ImmuCell (Livestock Operations), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of chicken farming services | 1961 | Riyadh, Saudi Arabia | – | – | – | |
Manufacturer of processed, nutritional & feed supplements, egg powder, frozen poultry products | 1971 | Pune, Maharashtra, India | USD 263.03 K | USD 397.23 M | 5,620 | |
Meat products are supplied to global markets from Israel. | 2019 | Rehovot, Central District, Israel | USD 9 M | – | 24 | |
Rusagro is recognized as a leading producer of sugar and edible oils in Russia. | 2003 | Moscow, Russia | – | – | – | |
Livestock animals are farmed and processed in an integrated approach. | 1983 | Dandong, Liaoning, China | – | USD 14.83 B | 49,900 | |
Sustainable feed additives for livestock are provided by Agteria. | 2023 | Stockholm, Sweden | USD 7.71 M | – | – | |
Livestock identification tags and tissue sampling units are manufactured. | 1972 | Dallas, Texas, United States | USD 106.01 M | – | – | |
Financial solutions, health products, and bird's nest exports are provided. | 1998 | Shah Alam, Selangor, Malaysia | – | USD 22.89 M | – | |
Beef, meat, and pork products are supplied to customers. | 2021 | Chicago, Illinois, United States | USD 11.5 M | – | – | |
Food and consumer products are produced via integrated agro-based operations. | 2011 | Shah Alam, Selangor, Malaysia | – | USD 1.74 B | 1 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ImmuCell
ImmuCell was founded in 1982 and raised its 1st funding round 34 years after it was founded.
ImmuCell is headquartered in Portland, United States. It is registered at Portland, Oregon, United States.
ImmuCell has 75 employees.
Annual revenue of ImmuCell is $27.64M as on Dec 31, 2025.
ImmuCell is engaged in developing, manufacturing, and marketing scientifically-proven products aimed at maximizing the genetic potential of dairy and beef cattle through disease prevention. Solutions are provided to address major issues like calf scours and mastitis, reducing reliance on antibiotics. The company operates within the animal health sector, offering innovative treatments and preventatives such as First Defense for scours and Re-Tain for mastitis. Commitment is shown to regulatory standards and customer-focused, cost-effective operations.
ImmuCell offers First Defense and Re-Tain.
Yes, ImmuCell is publicly traded on NASDAQ under the ticker symbol ICCC.
ImmuCell has 1 investor. Key investors include TD Bank.
ImmuCell operates through Immucell Corporation.